In addition, there are other signaling pathways than the MAPK axis (activated by BRAF and FGFR mutations, among others) which are altered in the pediatric-type diffuse low-grade gliomas—for example, MYB/MYBL1 amplifications and rearrangements have been identified in diffuse astrocytomas, becoming a new type of tumor in the last WHO classification update. Here, BRAF is linked to neoplasm.